(NASDAQ: THTX) Theratechnologies's forecast annual revenue growth rate of 16.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.63%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.72%.
Theratechnologies's revenue in 2025 is $62,456,296.On average, 1 Wall Street analysts forecast THTX's revenue for 2025 to be $4,234,759,750, with the lowest THTX revenue forecast at $4,234,759,750, and the highest THTX revenue forecast at $4,234,759,750. On average, 1 Wall Street analysts forecast THTX's revenue for 2026 to be $4,469,257,847, with the lowest THTX revenue forecast at $4,469,257,847, and the highest THTX revenue forecast at $4,469,257,847.
In 2027, THTX is forecast to generate $4,487,649,854 in revenue, with the lowest revenue forecast at $4,487,649,854 and the highest revenue forecast at $4,487,649,854.